PPT-CHAPTER 4   LIVER TRANSPLANTATION

Editors Dr Ganesalingam AL Kanagasabai   Expert panel Dr Ganesalingam AL Kanagasabai Chairperson Professor Dr Lee Way Seah Dr Lim Chooi Bee Dr Lim Kin Foong Dr Haniza Binti Omar Table . Associate Professor of Medicine. Division of . Gastroenterology. /Hepatology. University of Utah Health Sciences Center. Referral for Liver Transplantation Evaluation. Last . Updated: . September . 3. Prof . Khaled. . Yassen. MD FFARCSI. Department of . Anaesthesia. Liver Institute, . Menoufiya. University, Egypt.. kyassen61@hotmail.com. Old and New Liver Institute, . Menoufiya. University, Egypt. U. nusual Cases. . . . Ahmet. . Gurakar. , MD. . . Johns Hopkins School of Medicine. Medical Director, Liver Transplant Program . Design. Open-label. CURRY . Study. : SOF + RBV for HCV with liver cancer before transplantation. ≥ 18 years. Chronic HCV infection. Any g. enotype. HCV RNA ≥ 10,000 IU. /ml. Treatment naïve or not. Bertus Eksteen. Aspen Woods Clinic and University of Calgary . Canada. Important considerations. Predicting timing to list for transplant. Risk of death without transplant. Year 1 liver transplant mortality 10-12%. Associate Professor of Medicine. Division of . Gastroenterology. /Hepatology. University of Utah Health Sciences Center. Referral for Liver Transplantation Evaluation. Last . Updated: . September . 3. Jessica Wen, M.D.. The Children’s Hospital of Philadelphia. Nov. 3, 2018. Objectives. P. rimary functions of the liver. I. ndications . for Liver . Transplant. P. rocess of liver transplant evaluation and listing. SLIDE SET. Introduction. Source: Annual Report for Liver Transplantation 2014/15, NHS Blood and Transplant. Source: Annual Report on Liver Transplantation 2020/21, NHS Blood and Transplant. Source: Annual Report for Liver Transplantation 2014/15, NHS Blood and Transplant. Milan Kinkhabwala, MD. Professor of Surgery . Director of Abdominal Transplantation. Montefiore Einstein Center for Cancer Care. History of Transplant. Understanding of . Alloimmunity. : Medawar et al 1950’s. 23 European Review for Medical and Pharmacological Sciences2017; 21 (1 Suppl): 23-36 F.R. PONZIANI1, S. BHOORI2, M. POMPILI1, M.A. ZOCCO1, M. BIOLATO1, G. MARRONE1, A. GASBARRINI1, V. MAZZAFERRO2, A. 1 EFSUMB – Editor: Christoph F. Dietrich Liver Transplantation Fabio Piscaglia 1 MD PhD, Paul Sidhu 2 BSc MBBS MRCP FRCR, Knut Brabrand 3 MD and Alberto Borghi 4 MD PhD 1 Department of Digestive This copy is uncontrolled unless printed on ‘Controlled’ paper(Template Version 07/10/08) Author(s): Kathy Zalewska Page 1 of 24 This Policy replacesPOL195/Copy Number Summary of Significa SOLAR-2. Source: . Manns. M, et al. Lancet Infect Dis. 2016;16:685-97.. Treatment Naïve and Treatment Experienced, Phase 2. Ledipasvir-Sofosbuvir + Ribavirin in Advanced Liver Disease. SOLAR-2: Features. I. PAÚ. Transplantation. Transfer . of. . living. . tissue. . Cells. : stem . cells. , . blood. . cells. – . platelets. , …. Tissue. : . blood. , bone . marrow. , skin, bone, . cartilage. , .